Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefmetazol + cefotiam
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Cefmetazol + cefotiam is a combination of two beta-lactam antibiotics: cefmetazol, a cephamycin, and cefotiam, a second-generation cephalosporin. Both drugs act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to bactericidal activity against susceptible organisms. This combination has been studied for its synergistic effects against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (MSSA), with in vitro studies showing enhanced antibacterial activity compared to either agent alone. The synergy is particularly notable at lower concentrations and may be useful in treating infections caused by resistant staphylococci[1][2][3][5]. Each component covers a broad spectrum of gram-positive and gram-negative bacteria.
- Brand names
- ZefazoneCeradonPansporin
- Other names
- cefmetazole + cefotiam
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on cefmetazol + cefotiam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefmetazol + cefotiam.